A collaboration to expand autologous CAR-T programs into trials for multiple cancers in a cost-efficient way, has been formed by BioNTech SE and Autolus Therapeutics plc.
The German mRNA giant BioNTech has sealed a pact worth up to $1 billion with Biotheus to develop the Chinese biotech company’s bispecific antibody cancer drug PM8002 in all territories except for Greater China.
BioNTech and Pfizer have received a positive opinion from The Committee for Medicinal Products for Human Use (CHMP) for their updated COVID-19 vaccine, as a single dose for individuals 5 years of age and older, regardless of prior vaccination history,...
BioNTech and Duality Biologics have entered into exclusive license and collaboration agreements for two ADC assets: thus adding ADCs as an additional drug class in BioNTech’s oncology portfolio.
BioNTech and OncoC4 have announced a worldwide license and collaboration agreement to develop and commercialize OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications....
BioNTech and Israel's Weizmann Institute of Science have signed a Memorandum of Understanding (MoU) to partner on research on cancer, infectious disease and neurodegenerative diseases at BioNTech’s new mRNA Excellence Center. BioNTech will also create...
mRNA therapeutics have received increased amounts of attention and funding ever since mRNA vaccines proved effective in curbing the spread of the COVID-19 pandemic. Now, researchers are exploring mRNA therapeutics’ use in other disease spaces, reports...
German mRNA pioneer BioNTech will acquire InstaDeep, an artificial intelligence and machine learning specialist, for around £362m ($439m): pledging to incorporate rapidly evolving AI capabilities into its research, drug discovery, manufacturing and deployment...
BioNTech and the UK government have signed a wide-reaching Memorandum of Understanding (MoU): with one of the goals to provide up to 10,000 patients with personalized mRNA cancer immunotherapies by 2030.
BioNTech has dosed the first participant in a Phase 1 trial for BNT163, a herpes simplex virus (HSV) vaccine candidate for HSV-2 and potentially HSV-1.
BioNTech will create its first regional clinical trial sites in East Asia: with the launch of activities in Taiwan for an mRNA head and neck cancer candidate.
BioNTech will create an mRNA facility in Singapore through the acquisition of a Novartis site: which will become its Regional Headquarters and production center for the Asia Pacific region.
BioNTech is set to take several mRNA candidates into clinical trials over the coming months: including vaccines for shingles, malaria and tuberculosis.
As the US government stops buying COVID-19 shots, Pfizer said the vaccine it developed with BioNTech will be sold for US$110 to US$130 per dose, from as early as the first quarter 2023.
BioNTech will establish an mRNA research and innovation center in Victoria, alongside clinical scale manufacturing capabilities. Meanwhile, it has also pledged to step up clinical development of oncology therapies in the country.
Pfizer and BioNTech have completed their application to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine: saying they stand ready to start shipping...
BioNTech and Genmab are expanding a global collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients: with the first monospecific antibody candidate expected to enter clinical trials by the end of the year.
CureVac has filed a lawsuit in a German regional court against BioNTech SE: seeking ‘fair compensation for infringement… of CureVac’s intellectual property rights’ regarding tech used in the manufacture of the Pfizer/BioNTech COVID-19 vaccine. BioNTech,...
Construction works on an mRNA manufacturing facility have started in Kigali, Rwanda: as BioNTech works to create a pan-African end-to-end manufacturing network for mRNA-based vaccines.
Germany has made a series of contracts with vaccine manufacturers to reserve mRNA manufacturing capacity in the country as part of its pandemic preparedness plans.
Moderna announced a new supply agreement with the Swiss federal government today for seven million doses of its COVID-19 booster vaccine for anticipated delivery in 2023.
Pfizer and BioNTech expect to produce four billion doses of their COVID-19 vaccine in 2022: regardless of whether the current vaccine or a new Omicron specific vaccine is needed.
BioNTech and Crescendo, a clinical stage immuno-oncology company developing targeted T cell enhancing therapeutics, have entered a multi-target discovery collaboration to develop novel immunotherapies for cancer and other diseases.
Two doses of the Pfizer/BioNTech vaccine ‘may not be sufficient’ to protect against infection with the Omicron variant; but three doses of the vaccine neutralize the variant, according to a preliminary laboratory study released by the companies.
The European Medicines Agency’s human medicines committee (CHMP) has recommended granting an extension of indication for the Pfizer/BioNTech COVID-19 vaccine to include use in children aged 5 to 11.
Aceto expands GMP product lines for biopharmaceutical and vaccine manufacturing with acquisition of A&C Bio Buffer, growing its manufacturing footprint and strengthening its presence in Europe.
Pfizer and BioNTech are lining up orders of their COVID-19 vaccine for next year and beyond, predicting total capacity in 2022 to rise to 4 billion doses.
BioNTech aims to develop the first mRNA-based malaria vaccine, hoping to reach clinical trials by 2022. Meanwhile, it is also exploring possibilities to set up mRNA manufacturing facilities on the African continent – which could potentially be used for...
Pfizer and BioNTech’s deal with the US Government to supply an additional 200 million doses of its COVID-19 vaccine is the latest in the series of new orders.
The European Commission today announced that it has reserved an additional 1.8 billion doses of the coronavirus vaccine developed by Pfizer-BioNTech, on behalf of all 27 EU countries, from the end of 2021 to 2023.
The US Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for Pfizer and BioNTech’s COVID-19 vaccine: now including adolescents aged 12-15 years old.
BioNTech plans to expand its global footprint with a regional headquarters for South East Asia in Singapore; as well as a fully integrated mRNA manufacturing facility.
